文献速递神经免疫

那他珠单抗对继发进展型多发性硬化疾病进展的影响(ASCEND):一项3期随机双盲安慰剂对照试验及开放标签扩展研究

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension.
PubMed 文献 · Lancet Neurol · 2018-03-12

ASCEND为3期随机双盲安慰剂对照试验,纳入889例继发进展型多发性硬化患者,每4周静脉给予300 mg那他珠单抗或安慰剂2年;主要复合残疾终点无显著获益(OR 0.86,95%CI 0.66-1.13,p=0.287),但上肢9HPT组分进展减少(OR 0.56,95%CI 0.40-0.80,名义p=0.001);作者认为需更长期试验评估其他残疾组分获益。

要点

  • 那他珠单抗未减少继发进展型多发性硬化主要复合残疾终点进展(OR 0.86,95%CI 0.66-1.13,p=0.287)。
  • 那他珠单抗减少9HPT上肢组分进展(OR 0.56,95%CI 0.40-0.80,名义p=0.001)。
  • 未发生进行性多灶性白质脑病,2例死亡均与研究治疗无关。

核心结论

  • 那他珠单抗治疗继发进展型多发性硬化未减少主要多组分残疾终点的进展,但减少了其上肢组分的进展。

研究设计与样本

  • ASCEND为3期随机双盲安慰剂对照试验(第1部分)及可选2年开放标签扩展(第2部分),纳入18-58岁那他珠单抗初治、继发进展型多发性硬化≥2年、既往1年残疾进展与复发无关、EDSS 3.0-6.5分的患者。
  • 第1部分来自17个国家163个中心,按1:1随机接受每4周静脉300 mg那他珠单抗或安慰剂共2年,按中心和EDSS评分(3.0-5.5 vs 6.0-6.5)分层。
  • 2011年9月13日至2015年7月16日共随机889例(那他珠单抗组440例,安慰剂组449例),疗效和安全性分析基于意向治疗人群。

主要发现

  • 第1部分中,那他珠单抗组439例中195例(44%)与安慰剂组448例中214例(48%)出现确认的残疾进展(OR 0.86,95%CI 0.66-1.13,p=0.287)。
  • EDSS组分无治疗效应(OR 1.06,95%CI 0.74-1.53,名义p=0.753),T25FW组分无治疗效应(OR 0.98,95%CI 0.74-1.30,名义p=0.914)。
  • 那他珠单抗减少9HPT进展(OR 0.56,95%CI 0.40-0.80,名义p=0.001)。
  • 第1部分严重不良事件:安慰剂组100例(22%),那他珠单抗组90例(20%)。
  • 第2部分中,继续那他珠单抗者291例与那他珠单抗初治者274例接受那他珠单抗(中位随访160周,范围108-221周),严重不良事件分别为39例(13%)与24例(9%)。

关键数值与推荐

  • 主要终点为第1部分确认的持续残疾进展比例,由EDSS、T25FW和9HPT中一项或以上评估。
  • 第2部分主要终点为不良事件和严重不良事件的发生率。
  • 第1部分发生2例死亡,均认为与研究治疗无关;未发生进行性多灶性白质脑病。

临床怎么用

  • 作者认为,那他珠单抗治疗继发进展型多发性硬化未减少主要多组分残疾终点的进展,但减少了其上肢组分的进展。
  • 作者指出,需更长期试验评估治疗继发进展型多发性硬化是否可能在其他残疾组分产生获益。

局限性

  • 作者指出需更长期试验评估治疗继发进展型多发性硬化是否可能在其他残疾组分产生获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Although several disease-modifying treatments are available for relapsing multiple sclerosis, treatment effects have been more modest in progressive multiple sclerosis and have been observed particularly in actively relapsing subgroups or those with lesion activity on imaging. We sought to assess whether natalizumab slows disease progression in secondary progressive multiple sclerosis, independent of relapses. METHODS: ASCEND was a phase 3, randomised, double-blind, placebo-controlled trial (part 1) with an optional 2 year open-label extension (part 2). Enrolled patients aged 18-58 years were natalizumab-naive and had secondary progressive multiple sclerosis for 2 years or more, disability progression unrelated to relapses in the previous year, and Expanded Disability Status Scale (EDSS) scores of 3·0-6·5. In part 1, patients from 163 sites in 17 countries were randomly assigned (1:1) to receive 300 mg intravenous natalizumab or placebo every 4 weeks for 2 years. Patients were stratified by site and by EDSS score (3·0-5·5 vs 6·0-6·5). Patients completing part 1 could enrol in part 2, in which all patients received natalizumab every 4 weeks until the end of the study. Throughout both parts, patients and staff were masked to the treatment received in part 1. The primary outcome in part 1 was the proportion of patients with sustained disability progression, assessed by one or more of three measures: the EDSS, Timed 25-Foot Walk (T25FW), and 9-Hole Peg Test (9HPT). The primary outcome in part 2 was the incidence of adverse events and serious adverse events. Efficacy and safety analyses were done in the intention-to-treat population. This trial is registered with ClinicalTrials.gov, number NCT01416181. FINDINGS: Between Sept 13, 2011, and July 16, 2015, 889 patients were randomly assigned (n=440 to the natalizumab group, n=449 to the placebo group). In part 1, 195 (44%) of 439 natalizumab-treated patients and 214 (48%) of 448 placebo-treated patients had confirmed disability progression (odds ratio [OR] 0·86; 95% CI 0·66-1·13; p=0·287). No treatment effect was observed on the EDSS (OR 1·06, 95% CI 0·74-1·53; nominal p=0·753) or the T25FW (0·98, 0·74-1·30; nominal p=0·914) components of the primary outcome. However, natalizumab treatment reduced 9HPT progression (OR 0·56, 95% CI 0·40-0·80; nominal p=0·001). In part 1, 100 (22%) placebo-treated and 90 (20%) natalizumab-treated patients had serious adverse events. In part 2, 291 natalizumab-continuing patients and 274 natalizumab-naive patients received natalizumab (median follow-up 160 weeks [range 108-221]). Serious adverse events occurred in 39 (13%) patients continuing natalizumab and in 24 (9%) patients initiating natalizumab. Two deaths occurred in part 1, neither of which was considered related to study treatment. No progressive multifocal leukoencephalopathy occurred. INTERPRETATION: Natalizumab treatment for secondary progressive multiple sclerosis did not reduce progression on the primary multicomponent disability endpoint in part 1, but it did reduce progression on its upper-limb component. Longer-term trials are needed to assess whether treatment of secondary progressive multiple sclerosis might produce benefits on additional disability components. FUNDING: Biogen.

来源:Lancet Neurol,查看原文。版权归原作者所有。

引用

  1. Kapoor R, Ho PR, Campbell N, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018. PMID: 29545067. doi:10.1016/S1474-4422(18)30069-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。